Intravital Imaging of CD8+ T Cell Function in Cancer

Overview

Journal Clin Exp Metastasis

Specialty Oncology

Date 2008 Jul 31

PMID 18665448

Citations 16

Authors

Thorsten R Mempel

Christian A Bauer

Affiliations

Soon will be listed here.

Abstract

Recent technological advances in photonics are making intravital microscopy (IVM) an increasingly powerful approach for the mechanistic exploration of biological processes in the physiological context of complex native tissue environments. Direct, dynamic and multiparametric visualization of immune cell behavior in living animals at cellular and subcellular resolution has already proved its utility in auditing basic immunological concepts established through conventional approaches and has also generated new hypotheses that can conversely be complemented and refined by traditional experimental methods. The insight that outgrowing tumors must not necessarily have evaded recognition by the adaptive immune system, but can escape rejection by actively inducing a state of immunological tolerance calls for a detailed investigation of the cellular and molecular mechanisms by which the anti-cancer response is subverted. Along with molecular imaging techniques that provide dynamic information at the population level, IVM can be expected to make a critical contribution to this effort by allowing the observation of immune cell behavior in vivo at single cell-resolution. We review here how IVM-based investigation can help to clarify the role of cytotoxic T lymphocytes (CTL) in the immune response against cancer and identify the ways by which their function might be impaired through tolerogenic mechanisms.

Citing Articles

Understanding the in vivo Fate of Advanced Materials by Imaging.

Li R, Ng T, Garlin M, Weissleder R, Miller M Adv Funct Mater. 2024; 30(37).

PMID: 38545084 PMC: 10972611. DOI: 10.1002/adfm.201910369.

TLR agonist rMBP-NAP inhibits B16 melanoma tumor growth via induction of DCs maturation and T-cells cytotoxic response.

Liu J, Ding C, Wang X, Yang L, Liu X, Kang Q Cytotechnology. 2022; 74(4):459-467.

PMID: 36110155 PMC: 9374861. DOI: 10.1007/s10616-022-00532-4.

Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling.

Butner J, Martin G, Wang Z, Corradetti B, Ferrari M, Esnaola N Elife. 2021; 10.

PMID: 34749885 PMC: 8629426. DOI: 10.7554/eLife.70130.

Regulatory T Cells: Concept, Classification, Phenotype, and Biological Characteristics.

Du Y, Fang Q, Zheng S Adv Exp Med Biol. 2021; 1278:1-31.

PMID: 33523440 DOI: 10.1007/978-981-15-6407-9_1.

Reduced CTL motility and activity in avascular tumor areas.

Manaster Y, Shipony Z, Hutzler A, Kolesnikov M, Avivi C, Shalmon B Cancer Immunol Immunother. 2019; 68(8):1287-1301.

PMID: 31253998 PMC: 11028152. DOI: 10.1007/s00262-019-02361-5.

References

Mempel T, Junt T, von Andrian U . Rulers over randomness: stroma cells guide lymphocyte migration in lymph nodes. Immunity. 2006; 25(6):867-9. DOI: 10.1016/j.immuni.2006.11.002. View

Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen K . Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature. 1994; 369(6475):31-7. DOI: 10.1038/369031a0. View

Skokos D, Shakhar G, Varma R, Waite J, Cameron T, Lindquist R . Peptide-MHC potency governs dynamic interactions between T cells and dendritic cells in lymph nodes. Nat Immunol. 2007; 8(8):835-44. DOI: 10.1038/ni1490. View

von Andrian U, Mempel T . Homing and cellular traffic in lymph nodes. Nat Rev Immunol. 2003; 3(11):867-78. DOI: 10.1038/nri1222. View

Bousso P, Robey E . Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat Immunol. 2003; 4(6):579-85. DOI: 10.1038/ni928. View

Okada T, Cyster J . CC chemokine receptor 7 contributes to Gi-dependent T cell motility in the lymph node. J Immunol. 2007; 178(5):2973-8. DOI: 10.4049/jimmunol.178.5.2973. View

Miller M, Safrina O, Parker I, Cahalan M . Imaging the single cell dynamics of CD4+ T cell activation by dendritic cells in lymph nodes. J Exp Med. 2004; 200(7):847-56. PMC: 2213293. DOI: 10.1084/jem.20041236. View

Miller M, Wei S, Cahalan M, Parker I . Autonomous T cell trafficking examined in vivo with intravital two-photon microscopy. Proc Natl Acad Sci U S A. 2003; 100(5):2604-9. PMC: 151387. DOI: 10.1073/pnas.2628040100. View

Spiotto M, Rowley D, Schreiber H . Bystander elimination of antigen loss variants in established tumors. Nat Med. 2004; 10(3):294-8. DOI: 10.1038/nm999. View

10.

Millard P, Henkart M, Reynolds C, Henkart P . Purification and properties of cytoplasmic granules from cytotoxic rat LGL tumors. J Immunol. 1984; 132(6):3197-204. View

11.

Mempel T, Scimone M, Rodrigo Mora J, von Andrian U . In vivo imaging of leukocyte trafficking in blood vessels and tissues. Curr Opin Immunol. 2004; 16(4):406-17. DOI: 10.1016/j.coi.2004.05.018. View

12.

Stoelcker B, Ruhland B, Hehlgans T, Bluethmann H, Luther T, Mannel D . Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am J Pathol. 2000; 156(4):1171-6. PMC: 1876893. DOI: 10.1016/S0002-9440(10)64986-3. View

13.

Mrass P, Takano H, Ng L, Daxini S, Lasaro M, Iparraguirre A . Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J Exp Med. 2006; 203(12):2749-61. PMC: 2118164. DOI: 10.1084/jem.20060710. View

14.

Gajewski T, Meng Y, Blank C, Brown I, Kacha A, Kline J . Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006; 213:131-45. DOI: 10.1111/j.1600-065X.2006.00442.x. View

15.

Koebel C, Vermi W, Swann J, Zerafa N, Rodig S, Old L . Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007; 450(7171):903-7. DOI: 10.1038/nature06309. View

16.

Kaplan D, Shankaran V, Dighe A, STOCKERT E, Aguet M, Old L . Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A. 1998; 95(13):7556-61. PMC: 22681. DOI: 10.1073/pnas.95.13.7556. View

17.

Stinchcombe J, Bossi G, Booth S, Griffiths G . The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity. 2001; 15(5):751-61. DOI: 10.1016/s1074-7613(01)00234-5. View

18.

Seki N, Brooks A, Carter C, Back T, Parsoneault E, Smyth M . Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol. 2002; 168(7):3484-92. DOI: 10.4049/jimmunol.168.7.3484. View

19.

Worbs T, Mempel T, Bolter J, von Andrian U, Forster R . CCR7 ligands stimulate the intranodal motility of T lymphocytes in vivo. J Exp Med. 2007; 204(3):489-95. PMC: 2137901. DOI: 10.1084/jem.20061706. View

20.

Wu N, Klitzman B, Dodge R, Dewhirst M . Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Res. 1992; 52(15):4265-8. View